Verstehen
Warning to women amid shortages of some HRT products
Überblick
Women have been warned against self-medicating or sharing medication amid supply disruptions affecting certain Hormone Replacement Therapy (HRT) products, such as Estradot transdermal and FemSeven Conti patches. Healthcare professionals and support groups urge patients to consult their GP or pharmacist for guidance on safe alternatives, noting that substitution protocols ensure matching active ingredients and doses.
Wichtige Punkte
- Supplies of HRT patch brands Estradot transdermal and FemSeven Conti have experienced manufacturing or distribution delays.
- The Department of Health confirmed supply disruptions, and Serious Shortage Protocols are in place for Estradot patches until 8 January 2027.
- Pharmacists and GPs have cautioned women against self-medicating, sharing HRT, or switching without professional advice due to potential side effects.
- Patients experiencing issues with alternative formulations are advised to contact their healthcare provider to discuss suitable options.